Open AccessPost COVID-19 Guillain-Barré-Syndrome (GBS)
Author(s) -
Mohammed M Al-Zadjali,
Emaad Al Shibli,
Mohammed A Al Maskari,
Arunodaya R. Gujjar,
Abdullah Al Asmi
Publication year - 2022
Publication title -
sultan qaboos university medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.258
H-Index - 27
eISSN - 2075-0528
pISSN - 2075-051X
DOI - 10.18295/squmj.6.2021.090
Subject(s) - medicine , guillain barre syndrome , covid-19 , weakness , complication , pediatrics , intravenous immunoglobulins , coronavirus , intensive care medicine , surgery , immunology , antibody , pathology , disease , outbreak , infectious disease (medical specialty)
Guillain-Barré-Syndrome (GBS) is one of the reported neurological manifestations linked to a severe acute respiratory syndrome caused by coronavirus 2 (SARS-CoV-2)(COVID-19). We are presenting a case of a 72-years-old male patient who attended Sultan Qaboos University Hospital with a history of progressive bilateral limbs weakness and numbness. After exclusion of other possible causes, a diagnosis of GBS induced by COVID-19 was made. He received Intravenous Immunoglobulin (IVIG) 0.4g/kg/day for 5 days. This diagnosis is in line with a rare complication of COVID-19. This case highlights the characteristics and the course of GBS following COVID-19 infection. Further studies are needed to characterize the manifestations and the course of various neuromuscular disorders in relation to COVID-19 infection.
Keywords: COVID-19, Guillain-Barré-Syndrome (GBS), IVIG, Oman